CAPITAL AMI trial

Related trials

Results

Endpoints and data reported in the trial's publication(s)

Endpoint	Events (%)		Relative Risk	95% CI
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI
In-hospital Death	2 / 86 (2,3%)	3 / 84 (3,6%)	0,65	[0,11;3,80]
In-hospital Reinfarction	3 / 86 (3,5%)	11 / 84 (13,1%)	0,27	[0,08;0,92]
In-hospital Recurrent unstable ischemia†	5 / 86 (5,8%)	15 / 84 (17,9%)	0,33	[0,12;0,86]
In-hospital Stroke	1 / 86 (1,2%)	1 / 84 (1,2%)	0,98	[0,06;15,36]
In-hospital Death, reinfarction, or stroke	5 / 86 (5,8%)	14 / 84 (16,7%)	0,35	[0,13;0,93]
In-hospital Primary end point	7 / 86 (8,1%)	18 / 84 (21,4%)	0,38	[0,17;0,86]
Death At 30 days	2 / 86 (2,3%)	3 / 84 (3,6%)	0,65	[0,11;3,80]
Reinfarction At 30 days	4 / 86 (4,7%)	11 / 84 (13,1%)	0,36	[0,12;1,07]
Recurrent unstable ischemia At 30 days	6 / 86 (7,0%)	15 / 84 (17,9%)	0,39	[0,16;0,96]
Stroke At 30 days	1 / 86 (1,2%)	1 / 84 (1,2%)	0,98	[0,06;15,36]
Death, reinfarction, or stroke At 30 days	6 / 86 (7,0%)	14 / 84 (16,7%)	0,42	[0,17;1,04]
Primary end point At 30 days	8 / 86 (9,3%)	18 / 84 (21,4%)	0,43	[0,20;0,94]
Death At 6 months	3 / 86 (3,5%)	3 / 84 (3,6%)	0,98	[0,20;4,70]
Reinfarction At 6 months	5 / 86 (5,8%)	12 / 84 (14,3%)	0,41	[0,15;1,11]
Recurrent unstable ischemia At 6 months	7 / 86 (8,1%)	17 / 84 (20,2%)	0,40	[0,18;0,92]
Stroke At 6 months	1 / 86 (1,2%)	1 / 84 (1,2%)	0,98	[0,06;15,36]
Death, reinfarction, or stroke At 6 months	8 / 86 (9,3%)	15 / 84 (17,9%)	0,52	[0,23;1,16]
Primary end point At 6 months	10 / 86 (11,6%)	20 / 84 (23,8%)	0,49	[0,24;0,98]

Endpoints used by the meta-analysis and data retained for this trial

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

stroke (fatal and non fatal)

1 / 86
1 / 84
classic 0,98 [0,06;15,36]

reinfarction

5 / 86
12 / 84
0,41 [0,15;1,11]

death, reinfarctus, stroke

8 / 86
15 / 84
0,52 [0,23;1,16]

All cause death

3 / 86
3 / 84
classic 0,98 [0,20;4,70]

recurrent angina

7 / 86
17 / 84
0,40 [0,18;0,92] 0 2 1.0

Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
Relative risks
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI	Endpoint definition in the trial	Ref
stroke (fatal and non fatal)	1 / 86 (1,2%)	1 / 84 (1,2%)	0,98	[0,06;15,36]	Stroke At 6 months	0
reinfarction	5 / 86 (5,8%)	12 / 84 (14,3%)	0,41	[0,15;1,11]	Reinfarction At 6 months	0
death, reinfarctus, stroke	8 / 86 (9,3%)	15 / 84 (17,9%)	0,52	[0,23;1,16]	Death, reinfarction, or stroke At 6 months	0
All cause death	3 / 86 (3,5%)	3 / 84 (3,6%)	0,98	[0,20;4,70]	Death At 6 months	0
recurrent angina	7 / 86 (8,1%)	17 / 84 (20,2%)	0,40	[0,18;0,92]	Recurrent unstable ischemia At 6 months	0
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 0:

Endpoint	Events rate		Absolute risk reduction (ARR)
Absolute risk reduction
Endpoint	Studied treat.	Control treat.	Absolute risk reduction (ARR)
stroke (fatal and non fatal)	1,16%	1,19%	-0,3‰
reinfarction	5,81%	14,29%	-84,7‰
death, reinfarctus, stroke	9,30%	17,86%	-85,5‰
All cause death	3,49%	3,57%	-0,8‰
recurrent angina	8,14%	20,24%	-121,0‰

Meta-analysis of all similar trials:

Reference(s)

Trials register #

Le May MR, Wells GA, Labinaz M, Davies RF, Turek M, Leddy D, Maloney J, McKibbin T, Quinn B, Beanlands RS, Glover C, Marquis JF, O'Brien ER, Williams WL, Higginson LA. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study).. J Am Coll Cardiol 2005 Aug 2;46:417-24

Pubmed | Hubmed | Fulltext

CAPITAL AMI study, 2005

Treatments

Patients

Method and design

Results

Endpoints and data reported in the trial's publication(s)

Endpoints used by the meta-analysis and data retained for this trial

Reference(s)

Digital discoveries